CENA, France – GANODOLEUM GANSERMATA CENA (GFMC) has a novel therapeutic potential in the treatment of Alzheimer’s disease.
The company is developing a compound to treat Alzheimer’s-related neuronal loss in the brain and, if approved by the European Medicines Agency, would be the first drug to target the disorder.
The company, which is based in the U.K., has created a new protein that contains a protein that helps in the production of the ganodolases, which break down the gans peptide.
Gansermatolase inhibitors have been shown to have a number of potential therapeutic applications, but the drugs are expensive and do not work for everyone.
“The problem is that the drugs can’t be used in every patient and they have limited effectiveness, so this compound could be an opportunity,” said Paul Jansson, CEO of GFMC, which has developed the new compound with Swiss drugmaker GlaxoSmithKline (GSK).GFMC’s drug, which it hopes to begin clinical trials in the next few years, would target Alzheimer’s patients by blocking the gens protein.
The drug would then allow the body to regenerate gans protein and increase levels of the protein in neurons.
“If we get the drugs approved in the European Union, we’ll have a treatment that’s effective in 80% of patients,” Jansson said.
The FDA recently approved two drugs to treat amyloid beta-1 and Alzheimer’s – the first of which was a drug that targeted the ganzodolase pathway.
The FDA also approved the second drug, the ganedogenone-4, which targets the brain’s beta-amyloid precursor protein (APP) and helps to reduce the severity of the disease.GFMC has a different approach to tackling the brain disorder.
The compound developed by the company is designed to block the enzyme in the amyloids biosynthesis pathway.
It is also made from the same ganodesoxyglutarate that is used to treat a range of conditions, including Alzheimer’s.
The protein, called GANODEOXYGLUTARATE, is produced by the enzyme that converts glucose into the molecule that is required for the body’s cells to divide and build proteins.
“Gansers are involved in the biosynthesis of the brain.
The gansers, if destroyed, will kill the brain,” Jansson said.GFMS has been developing its own ganzoderma luciferase inhibitor, GANSDOX, for about five years, Janssen said.
The new compound has been approved in Europe, and the company has plans to start clinical trials later this year in the United States.
The compound, which will not have a patent, will be tested on mice and rats to see if it is safe and effective in humans.
The first trial in humans is set to begin later this summer.
“This compound is not only a powerful drug for the brain, but it is also a safe and efficacious drug,” Janson said.
“We’re trying to be very selective about which patients we will be testing in the clinical trials.
It will be very different from anything we have done before.”GFMS said the compound has the potential to be used as a novel treatment for a wide range of neurodegenerative diseases.
“It is not just a brain disease, it is the heart of the nervous system,” Jansen said.